Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
By Jim Kling. November 7th 2024. Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to target the BCR-ABL fusion in chronic myelogenous leukemia. FDA Grants Orphan …
High-Dose Radiation Plus Long-Term ADT Improves Survival in …
Jan 25, 2024 · Utilizing a higher dose of radiation therapy in combination with the long-term use of androgen deprivation therapy (ADT) improved survival outcomes after 10 years of follow-up in patients with high-risk prostate cancer, according to long-term results from the GETUG-AFU 18 trial (NCT00967863) presented at the 2024 ASCO Genitourinary Cancers ...
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
Dec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
Sequencing Matters: Giving Radium-223 Prior to Docetaxel Leads …
Sep 16, 2024 · The use of radium-223 (Xofigo) prior to docetaxel in symptomatic metastatic castration resistant prostate cancer (mCRPC) demonstrated better quality of life (QOL) and tolerability scores over the converse sequence of docetaxel prior to radium-223, according to findings from the phase 2 RAPSON trial (NCT03230734).1 Results also demonstrated no difference between the treatment arms for ...
San Antonio Breast Cancer Symposium - Targeted Oncology
SIM0270 Shows Early Antitumor Activity in ER+/HER2– Advanced/Metastatic Breast Cancer. Ashling Wahner. December 8th 2023. The brain-penetrant oral selective estrogen receptor degrader SIM0270 exhibited a favorable safety profile and early signals of antitumor activity in patients with estrogen receptor-positive, HER2-negative locally advanced ...
Precision Medicine Implemented in the Community Oncology …
Mar 15, 2024 · Precision medicine has emerged as a cornerstone of cancer care, ensuring that patients receive the highest quality of personalized treatment. Its application extends to identifying at-risk individuals, preventing cancer, tailoring therapies, and monitoring treatment efficacy. However, community-based oncology practices face unique challenges in ...
September 2024 FDA Roundup: Key Decisions Drive Oncology …
In September 2024, the FDA made several significant strides in oncology. Notably, the agency approved a subcutaneous formulation of atezolizumab (Tecentriq) for various cancer types, offering a more convenient administration option for patients. Additionally, ribociclib (Kisqali) was granted approval for early-stage breast cancer, expanding ...
RMC-9805 Hits Milestone in Early-Phase Clinical Trial of KRAS …
Sep 24, 2023 · The oral, covalent, mutant-selective KRAS inhibitor, RMC-9805, has been dosed for the first time in a patient with a KRAS -G12D-mutant solid tumor, marking the beginning of a phase 1/1b clinical trial (NCT06040541). 1. The study follows a multicenter, open-label, dose-escalation, and dose-expansion design.
Targeting STK11 Mutations in Cancer - Targeted Oncology
Jan 29, 2022 · David R. Gandara, MD. STK11 mutation recently have become a biomarker and potential target of interest, especially for patients with lung cancer. Recent trials explore drugs like bemcentinib, everolimus, talazoparib, and others for potential approaches to …
Trastuzumab Deruxtecan in DESTINY-Breast04 Meets Key End …
Feb 23, 2022 · Destiny-Breast04 is a study of about 557 patients with HER2-low, unresectable and/or metastatic breast cancer who are treated with either trastuzumab deruxtecan or chemotherapy of physician’s choice. The study follows a multicenter, randomized, open-label, active controlled trial design with a goal of determining the safety and efficacy of ...